- Home
- TERN
as 04-21-2025 4:00pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 298.1M | IPO Year: | 2021 |
| Target Price: | $18.38 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.86 - $11.40 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Terns Pharmaceuticals Inc. (TERN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kuriakose Emil | TERN | Chief Medical Officer | Apr 1 '25 | Sell | $2.49 | 952 | $2,365.82 | 53,317 | |
| Burroughs Amy L. | TERN | Chief Executive Officer | Jan 30 '25 | Buy | $5.11 | 510 | $2,606.10 | 19,609 | |
| Jung Melita Sun | TERN | Chief Business Officer | Jan 30 '25 | Buy | $5.11 | 2,250 | $11,497.50 | 2,250 |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
Zacks
15 days ago
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Zacks
19 days ago
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
GlobeNewswire
19 days ago
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Zacks
a month ago
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
GlobeNewswire
a month ago
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Motley Fool
a month ago
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
MT Newswires
2 months ago
William Blair Initiates Terns Pharmaceuticals at Market Perform
GlobeNewswire
2 months ago
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.